D. Boral Capital upgraded CorMedix (CRMD) to Buy from Hold with a $14 price target after the company reported preliminary Q3 results. The “robust” sales in Q3 and visibility into near-term operating synergies, as well as the recent stock pullback, lead the firm to raise its rating and reinstate its $14 target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix reports preliminary Q3 unaudited net revenue more than $100M
- CorMedix raises FY25 pro forma net revenue view to $375M from $325M-$350M
- CorMedix files to sell 6.32M shares of common stock for holders
- Largest borrow rate increases among liquid names
- CorMedix completes enrollment in Phase III ReSPECT trial for REZZAYO